INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 179 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2016. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $8,949,000 | +378.8% | 80,000 | +150.0% | 0.11% | +256.2% |
| Q4 2017 | $1,869,000 | +114.6% | 32,000 | +113.3% | 0.03% | +113.3% |
| Q3 2017 | $871,000 | -70.6% | 15,000 | -38.8% | 0.02% | -73.2% |
| Q2 2017 | $2,966,000 | +22.0% | 24,500 | +14.0% | 0.06% | +19.1% |
| Q1 2017 | $2,432,000 | +4.1% | 21,500 | 0.0% | 0.05% | -13.0% |
| Q4 2016 | $2,336,000 | -34.0% | 21,500 | 0.0% | 0.05% | -36.5% |
| Q3 2016 | $3,539,000 | +7.8% | 21,500 | -6.5% | 0.08% | 0.0% |
| Q2 2016 | $3,282,000 | -32.4% | 23,000 | -39.5% | 0.08% | -29.8% |
| Q1 2016 | $4,856,000 | -3.8% | 38,000 | +12.4% | 0.12% | -10.4% |
| Q4 2015 | $5,048,000 | -23.5% | 33,800 | -15.1% | 0.14% | -16.7% |
| Q3 2015 | $6,602,000 | -51.2% | 39,800 | -28.9% | 0.16% | -42.3% |
| Q2 2015 | $13,517,000 | -2.2% | 56,000 | +14.3% | 0.28% | +1.1% |
| Q1 2015 | $13,822,000 | +153.2% | 49,000 | +40.0% | 0.28% | +143.9% |
| Q4 2014 | $5,460,000 | – | 35,000 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WHITE SQUARE CAPITAL LLP | 65,500 | $7,117,000 | 11.05% |
| Ghost Tree Capital, LLC | 70,000 | $7,606,000 | 1.83% |
| Carmignac Gestion | 2,022,792 | $219,776,000 | 1.71% |
| Orbimed Advisors | 1,120,000 | $121,688,000 | 1.55% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 29,555 | $3,211,000 | 1.45% |
| Parametrica Management Ltd | 10,814 | $1,175,000 | 1.16% |
| BB BIOTECH AG | 255,719 | $27,784,000 | 1.03% |
| SECTORAL ASSET MANAGEMENT INC | 74,150 | $8,056,000 | 0.89% |
| ALTRINSIC GLOBAL ADVISORS LLC | 188,904 | $20,524,000 | 0.76% |
| FALCON POINT CAPITAL, LLC | 45,005 | $4,890,000 | 0.66% |